natgillin/translations-raw huggingface dataset:
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.8). 
U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa); međutim, prijavljeno vrijeme do nastupa poremećaja je različito pa se ti događaji mogu javiti i mjesecima nakon uvođenja liječenja (vidjeti dio 4.8).
Investigations common increased blood creatinine 
Pretrage često povišene vrijednosti kreatinina u krvi
Do not stop taking Symtuza without talking to your doctor first 
Nemojte prestati uzimati lijek Symtuza ako prethodno o tome niste razgovarali s liječnikom
Symtuza can be co-administered with H2-receptor antagonists without dose adjustments. 
Symtuza se može primjenjivati istodobno s antagonistima H2 receptora bez prilagodbe doze.
On rare occasions, these muscle disorders have been serious. 
U rijetkim su slučajevima ovi mišićni poremećaji bili ozbiljni. - upalni sindrom imunološke rekonstitucije.
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets 
Symtuza 800 mg/150 mg/200 mg/10 mg filmom obložene tablete
Cobicistat is a mechanism-based inhibitor of cytochrome P450 of the CYP3A subfamily. 
Kobicistat je inhibitor mehanizma djelovanja enzima citokroma P450 iz podskupine CYP3A.
Darunavir binds primarily to plasma α1-acid glycoprotein. 
Darunavir se prvenstveno vezuje za α1-kiseli glikoprotein u plazmi.
Concomitant use of everolimus or irinotecan and Symtuza is not recommended. 
Ne preporučuje se istodobna primjena everolimusa ili irinotekana i lijeka Symtuza.
Tell your doctor if you take: - Bosentan (to treat high blood pressure in the pulmonary circulation) - Dexamethasone (injection) (corticosteroid) - Boceprevir (to treat hepatitis C virus infection) - Rifapentine, rifabutin (to treat bacterial infections) - Oxcarbazepine (to prevent seizures). 
Obavijestite liječnika ako uzimate: - bosentan (za liječenje visokog krvnog tlaka u plućnoj cirkulaciji) - deksametazon (injekcija) (kortikosteroid) - boceprevir (za liječenje infekcija virusom hepatitisa C) - rifapentin, rifabutin (za liječenje bakterijskih infekcija) - okskarbazepin (za sprječavanje napadaja)
C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (approximately 86%) and faeces (approximately 14%). 
Nakon primjene C]-emtricitabina cijela je doza pronađena u mokraći (približno 86%) i fecesu (približno 14%).
HIV-1 isolates with the K65R mutation have low-level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine. 
Izolati virusa HIV-1 koji imaju mutaciju K65R pokazuju malo smanjenje osjetljivosti na abakavir, emtricitabin, tenofovir i lamivudin.
As limited information is available on the use of Symtuza in patients aged 65 and over, caution should be exercised, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy (see sections 4.2 and 5.2). 
Budući da su dostupni ograničeni podaci o primjeni lijeka Symtuza u bolesnika u dobi od 65 ili više godina, potrebno je postupati uz oprez zbog povećane učestalosti smanjene jetrene funkcije te popratnih bolesti ili druge terapije (vidjeti dijelove 4.2 i 5.2).
Darunavir is extensively metabolised by the hepatic CYP system and almost exclusively by isozyme CYP3A4. 
Darunavir se opsežno metabolizira putem jetrenog CYP sustava, gotovo isključivo izoenzimom CYP3A4.
For emtricitabine, the Cmax was 1.26-fold higher in a fasted condition, while the AUC was comparable in fed and fasted condition. 
Cmax emtricitabina bio je 1,26 puta veći kod primjene natašte, dok je AUC bio usporediv i kod primjene natašte i kod primjene nakon obroka.
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii 
Relevantni primjeri uključuju citomegalovirusni retinitis, generalizirane i/ili žarišne mikobakterijske infekcije te upala pluća izazvana uzročnikom Pneumocystis jirovecii (ranije poznatim kao Pneumocystis carinii).
Low levels of metabolites are observed in urine and feces and do not contribute to the CYP3A inhibitory activity of cobicistat. 
U mokraći i stolici pronađene su niske razine metabolita, koje ne pridonose inhibicijskom djelovanju kobicistata na CYP3A.
Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected. 
Nakon probne istodobne primjene s umjerenim induktorom CYP3A efavirenzom, izloženost tenofoviralafenamidu nije se značajno promijenila.
Tenofovir alafenamide is minimally metabolised by CYP3A4. 
Tenofoviralafenamid se minimalno metabolizira putem CYP3A4.
Symtuza should not be used in paediatric patients below 3 years of age because of safety concerns (see sections 4.4 and 5.3). 
Symtuza se ne smije primjenjivati u pedijatrijskih bolesnika mlađih od 3 godine zbog sigurnosnih razloga (vidjeti dijelove 4.4 i 5.3).
Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). 
Emtricitabin se prvenstveno izlučuje putem bubrega, pa se čitava doza pronalazi u mokraći (približno 86%) i fecesu (približno 14%).
Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). 
Tenofoviralafenamid se prenosi P-glikoproteinom (P-gp) i proteinom koji uzrokuje otpornost raka dojke na liječenje (engl. breast cancer resistance protein, BCRP).
There were insufficient pharmacokinetic data in the clinical trials to determine the effect of hepatitis B and/or C virus infection on the pharmacokinetics of darunavir,cobicistat, emtricitabine, or tenofovir alafenamide (refer to sections 4.4 and 4.8). 
Istodobna infekcija virusom hepatitisa B i/ili hepatitisa C Nije bilo dovoljno farmakokinetičkih podataka iz kliničkih ispitivanja da bi se utvrdio utjecaj infekcije virusom hepatitisa B i/ili C na farmakokinetiku darunavira, kobicistata, emtricitabina ili tenofoviralafenamida (vidjeti dijelove 4.4 i 4.8).
For tenofovir alafenamide, the Cmax was 1.82-fold higher in fasted condition, while the AUC was 20% lower to comparable in a fasted compared to fed condition. 
Cmax tenofoviralafenamida bio je 1,82 puta veći kod primjene natašte, dok je AUC bio 20% niži kod primjene natašte nego kod primjene nakon obroka.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 mcg/mL. 
In vitro se za proteine u plazmi ljudi vezalo < 4% emtricitabina; vezivanje je bilo neovisno o koncentraciji u rasponu od 0,02 do 200 µg/ml.
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and cobicistat, resulting in lowered plasma concentrations of darunavir and cobicistat (e.g. efavirenz, carbamazepine, phenytoin, phenobarbital, rifampicin, rifapentine, rifabutin, St. John's wort) (see section 4.3 and interaction table below). 
Očekuje se da bi lijekovi koji induciraju aktivnost CYP3A mogli povećati klirens darunavira i kobicistata te tako dovesti do sniženja plazmatskih koncentracija darunavira i kobicistata (npr. efavirenz, karbamazepin, fenitoin, fenobarbital, rifampicin, rifapentin, rifabutin, gospina trava) (vidjeti dio 4.3 i tablicu u nastavku).
In the Phase 3 trial of Symtuza in treatment-naïve patients, increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL and HDL cholesterol, and triglycerides at Week 48 and 96 (see Table 3). 
U ispitivanju faze 3 lijeka Symtuza provedenom u prethodno neliječenih bolesnika primijećena su povišenja početnih vrijednosti lipidnih parametara natašte (ukupni kolesterol, direktni LDL i HDL kolesterol te trigliceridi) u 48. i 96. tjednu (vidjeti Tablicu 3).
DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) and Stevens-Johnson syndrome has been rarely (< 0.1%) reported, and during post-marketing experience toxic epidermal necrolysis and acute generalised exanthematous pustulosis have been reported. 
Drug Rash with Eosinophilia and Systemic Symptoms, DRESS) te Stevens-Johnsonova sindroma, a nakon stavljanja lijeka u promet prijavljene su toksična epidermalna nekroliza i akutna generalizirana egzantematozna pustuloza.
Concomitant use of a HMG CoA reductase inhibitor and Symtuza may increase plasma concentrations of the lipid lowering agent, which may lead to adverse reactions such as myopathy. 
Istodobna primjena inhibitora HMG-CoA reduktaze i lijeka Symtuza može povisiti plazmatske koncentracije lijeka za snižavanje razine lipida, što može dovesti do nuspojava kao što je miopatija.
In the Phase 3 trial in suppressed treatment-experienced patients (EMERALD Study TMC114IFD3013), 5.1% (39/763) of patients receiving Symtuza experienced rash (most of which were grade 1), none discontinued treatment due to rash. 
U ispitivanju faze 3 u virološki suprimiranih bolesnika koji su primali terapiju (EMERALD ispitivanje TMC114IFD3013), 5,1% (39/763) bolesnika koji su uzimali lijek Symtuza doživjelo je osip (većinom 1. stupnja), nitko nije prekinuo liječenje radi osipa.
Over 96 weeks of treatment in the Phase 3 studies TMC114FD2HTX3001 (AMBER) in treatmentnaïve patients and TMC114IFD3013 (EMERALD) in virologically suppressed treatment-experienced patients, resistance testing was performed on samples from patients experiencing protocol-defined virologic failure (PDVF) and who had HIV-1 RNA ≥400 copies/mL at failure or at later time points. 
Tijekom 96 tjedana liječenja u ispitivanjima faze 3: TMC114FD2HTX3001 (AMBER) u bolesnika koji prethodno nisu bili liječeni i TMC114IFD3013 (EMERALD) u prethodno liječenih virološki suprimiranih bolesnika, provedeno je testiranje rezistencije na uzorcima bolesnika koji su doživjeli protokolom definiran virološki neuspjeh i koji su imali HIV-1 RNK ≥ 400 kopija/ml u trenutku utvrđivanja neuspjeha liječenja ili pri kasnijem mjerenju.
When Symtuza is coadministered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia. 
Kada se Symtuza istodobno primjenjuje s lijekovima koji sadrže drospirenon preporučuje se kliničko praćenje, radi rizika nastanka hiperkalemije.
The most frequent (> 5%) adverse reactions reported in suppressed treatment-experienced patients (EMERALD Study TMC114IFD3013, Week 96 analysis) were diarrhoea (10.5%), headache (10.4%), arthralgia (7.7%), abdominal pain (7.5%), fatigue (5.9%), and rash (5.1%). 
Najčešće nuspojave (> 5%) prijavljene u prethodno liječenih virološki suprimiranih bolesnika (ispitivanje EMERALD, TMC114IFD3013, analiza podataka u 96. tjednu) bile su proljev (10,5%), glavobolja (10,4%), artralgija (7,7%), bol u abdomenu (7,5%), umor (5,9%) i osip (5,1%).
An open-label, Phase 2 trial (TMC114-C230) was conducted for evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 12 ART-naïve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg. 
Provedeno je otvoreno ispitivanje faze 2 (TMC114-C230) radi ocjenjivanja farmakokinetike, sigurnosti, podnošljivosti i djelotvornosti darunavira u kombinaciji s niskom dozom ritonavira u 12 pedijatrijskih bolesnika zaraženih virusom HIV-1 u dobi od 12 do manje od 18 godina i tjelesne težine od najmanje 40 kg koji se prethodno nisu liječili antiretrovirusnom terapijom.
Co-administration of Symtuza and these anticoagulants is not recommended. 
Ne preporučuje se istodobna primjena lijeka Symtuza i ovih antikoagulansa.
At Week 96, the median change in eGFRCG was -5.2 mL/min with D/C/F/TAF. 
Medijan promjene vrijednosti eGFRCG u 96. tjednu iznosio je -5,2 ml/min uz D/K/F/TAF.
Clinical monitoring is recommended when co-administering Symtuza with these sedatives/hypnotics and a lower dose of the sedative/hypnotic should be considered. 
Kod istodobne primjene lijeka Symtuza i ovih sedativa/hipnotika preporučuje se kliničko praćenje te treba razmotriti nižu dozu ovih sedativa/hipnotika.
It is important not to stop taking Symtuza without talking to your doctor first. 
Važno je da ne prestanete uzimati lijek Symtuza ako prethodno o tome niste razgovarali s liječnikom.
Baseline CD4+ cell count < 200 cells/mm ≥ 200 cells/mm 
Početna vrijednost broja CD4+ stanica <200 stanica/mm ≥200 stanica /mm
Metabolism and nutrition disorders common diabetes mellitus, anorexia, hypercholesterolaemia, low density lipoprotein increased, hypertriglyceridaemia, hyperlipidaemia, dyslipidaemia uncommon hyperglycaemia 
Poremećaji metabolizma i prehrane često dijabetes melitus, anoreksija, hiperkolesterolemija, povišeni lipoproteini niske gustoće, hipertrigliceridemija, hiperlipidemija, dislipidemija manje često hiperglikemija
Patients with pre-existing liver dysfunction, including chronic hepatitis B or C, have an increased risk for liver function abnormalities including severe and potentially fatal hepatic adverse reactions. 
Bolesnici s postojećom disfunkcijom jetre, uključujući kronični hepatitis B ili C, izloženi su povećanom riziku od poremećaja jetrene funkcije, uključujući potencijalno smrtonosne jetrene nuspojave.
2 consecutive HIV-1 RNA ≥ 50 copies/mL, or in case of discontinuation or at Week 48/96 for any reason, (single) HIV-1 RNA ≥ 50 copies/mL as of baseline (included) 
2 uzastopna mjerenja HIV-1 RNK ≥ 50 kopija/mL, ili u slučaju prekida ili u 48./96. tjednu radi bilo kojeg razloga, (jedno mjerenje) HIV-1 RNK ≥ 50 kopija/mL od početka liječenja (uključeno)
Table 7: Virologic Outcome in ART- naïve Adolescents at Week 48 (TLOVR algorithm) TMC114-C230 
Tablica 7: Virološki ishod u adolescenata prethodno neliječenih antiretrovirusnom terapijom u 48. tjednu (algoritam vremena do gubitka virološkog odgovora [engl. time to loss of virological response, TLOVR]) TMC114-C230
Patients with severe (Child-Pugh Class C) hepatic impairment. 
Bolesnici s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C).
The exposure to darunavir and cobicistat administered as the Symtuza was 30-45% lower and 16-29% lower, respectively, in fasted compared to fed condition. 
Izloženost darunaviru i kobicistatu nakon primjene lijeka Symtuza bila je 30 - 45% odnosno 16 - 29% niža natašte nego nakon obroka.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). 
Tenofoviralafenamid je nukleotidni inhibitor reverzne transkriptaze (engl. nucleotide reverse transcriptase inhibitor, NtRTI) i fosforoamidatni predlijek tenofovira (analog 2'-deoksiadenozin monofosfata).
Rash is a common adverse drug reaction in patients treated with darunavir. 
Osip je česta nuspojava u bolesnika liječenih darunavirom.
Median Increase From Baseline at Week 48 D/C/F/TAF 
Medijani povišenja od početne vrijednosti 48. tjedan D/K/F/TAF
Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination. 
Tenofovirdifosfat inhibira replikaciju HIV-a ugradnjom u virusnu DNK uz pomoć RT HIV-a, što dovodi do prekida lanca DNK.
Symtuza can be co-administered with proton pump inhibitors without dose adjustments. 
Symtuza se može primjenjivati istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human PBMCs and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL). 
Darunavir pokazuje aktivnost protiv laboratorijskih sojeva i kliničkih izolata virusa HIV-1 te laboratorijskih sojeva virusa HIV-2 u akutno zaraženim linijama T-stanica, ljudskim mononuklearnim stanicama iz periferne krvi i ljudskim monocitima/makrofagima, uz medijan vrijednosti EC50 u rasponu od 1,2 do 8,5 nM (0,7 - 5,0 ng/ml).
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja KART-a može doći do upalne reakcije na asimptomatski prisutne ili na rezidualne oportunističke patogene, koja može uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
ERGOT DERIVATIVES e.g. 
DERIVATI ERGOTA npr.
In HIV infected patients with severe immune deficiency at the time of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika s HIV infekcijom i teškom imunodeficijencijom u trenutku uvođenja KART-a može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
In double-blind Phase 3 Trial TMC114FD2HTX3001 (AMBER), treatment-naïve patients were randomised to receive either Symtuza (N = 362) or a combination of fixed-dose combination of darunavir and cobicistat and fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (F/TDF) (N = 363) once daily. 
U dvostuko slijepom ispitivanju faze 3 TMC114FD2HTX3001 (AMBER), bolesnici koji prethodno nisu bili liječeni bili su randomizirani tako da prime ili lijek Symtuza (N = 362) ili kombinaciju fiksne kombinacije darunavira i kobicistata i fiksne kombinacije emtricitabina i tenofovirdizoproksilfumarata (F/TDF) (N = 363) jedanput na dan.
In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 mcg/mL. 
In vitro se za proteine u plazmi ljudi vezalo < 0,7% tenofovira; vezivanje je je bilo neovisno o koncentraciji u rasponu od 0,01 do 25 µg/ml.
A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 15 and 40 times greater, respectively, than those expected after administration of Symtuza. 
Primijećena je minimalna infiltracija histiocita u oku pasa kod izloženosti tenofoviralafenamidu i tenofoviru koja je bila približno 15 odnosno 40 puta veća od one očekivane nakon primjene lijeka Symtuza.
• allergic reactions such as nettle rash (urticaria), itching, decreased appetite (anorexia) 
• alergijske reakcije kao što su koprivnjača (urtikarija), svrbež
Patients had a median age of 46 years (range 19-78), 82% were male, 75.5% White, 20.9% Black, and 2.3% Asian. 
Medijan dobi bolesnika bio je 46 godina (raspon 19-78), 82% bilo je muškog spola, 75,5% bijele rase, 20,9% crne rase i 2,3% azijskog porijekla.
A trial of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B). 
Ispitivanje farmakokinetike kobicistata provedeno je u ispitanika s umjerenim oštećenjem jetrene funkcije koji nisu bili zaraženi virusom HIV-1 (Child-Pugh stadij B).
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with Symtuza has not been established. 
Nije utvrđena sigurna i učinkovita doza sidenafila za liječenje plućne arterijske hipertenzije kada se primjenjuje istodobno s lijekom Symtuza.
Co-administration of Symtuza and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and cobicistat and may result in increased plasma concentrations of darunavir and cobicistat (e.g. azole antifungals like clotrimazole). 
Istodobna primjena lijeka Symtuza i drugih lijekova koji inhibiraju CYP3A može smanjiti klirens darunavira i kobicistata te uzrokovati povišenje plazmatskih koncentracija darunavira i kobicistata (npr. antifungalni azoli poput klotrimazola).
• cobicistat, a booster (enhancer) of darunavir 
• kobicistat, pojačivač darunavira
Following administration of tenofovir alafenamide, plasma [ 
Nakon primjene tenofoviralafenamida, [
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. 
Tijekom antiretrovirusne terapije može doći do povećanja tjelesne težine i povišenja razine lipida i glukoze u krvi.
Symtuza is, therefore, contraindicated in patients with severe hepatic impairment. 
Stoga je lijek Symtuza kontraindiciran u bolesnika s teškim oštećenjem jetrene funkcije.
Virologic Response, % HIV-1 RNA < 50 copies/mL 
Virološki odgovor, % HIV-1 RNK <50 kopija/mL Razlika liječenja
Co-administration of amiodarone, dronedarone, ivabradine, quinidine, or ranolazine and Symtuza is contraindicated (see section 4.3). 
Istodobna primjena amiodarona, dronedarona, ivabradina, kinidina ili ranolazina i lijeka Symtuza je kontraindicirana (vidjeti dio 4.3).
In the Phase 2/3 trials in treatment-naïve patients, 12.7% (59/465) of patients receiving Symtuza experienced rash (most of which were grade 1), 1.5% (7/465) of patients discontinued treatment due to rash, of whom one for rash and hypersensitivity. 
U ispitivanjima faze 2/3 u bolesnika koji prethodno nisu bili liječeni, 12,7% (59/465) bolesnika koji uzimaju lijek Symtuza doživjelo je osip (većinom 1.stupnja), 1,5% (7/465) bolesnika prekinulo je liječenje radi osipa, od čega jedan radi osipa i prosjetljivosti.
Cobicistat is a mechanism based inhibitor of CYP3A, and a weak CYP2D6 inhibitor. 
Kobicistat je inhibitor mehanizma djelovanja CYP3A i slab inhibitor CYP2D6.
Darunavir is an inhibitor of CYP3A, a weak inhibitor of CYP2D6 and an inhibitor of P-gp. 
Darunavir je inhibitor CYP3A, slab inhibitor CYP2D6 i inhibitor P-glikoproteina.
Changes in measures of renal function 
Promjene u mjerama funkcije bubrega
Virologic Outcomes in AMBER at Week 48 and 96 (FDA Snapshot) Week 48 
Tablica 5: Virološki ishodi u ispitivanju AMBER u 48. i 96. tjednu (FDA Snapshot) 48. tjedan
Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose. 
Glavni put eliminacije tenofoviralafenamida u ljudi je metabolizam, kojim se razgradi > 80% peroralno primijenjene doze.
Mexiletine 
Meksiletin
These can include, but are not limited to, severe rash or rash accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia. 
Oni uključuju, između ostaloga, težak osip ili osip praćen vrućicom, opću malaksalost, umor, bolove u mišićima ili zglobovima, mjehuriće na koži, oralne lezije, konjunktivitis, hepatitis i/ili eozinofiliju.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Symtuza is required. 
U bolesnika s normalnom bubrežnom ili jetrenom funkcijom preporučuje se smanjenje doze kolhicina ili prekid liječenja kolhicinom ako je potrebno liječenje lijekom Symtuza.
No human data on the effect of darunavir, cobicistat, emtricitabine, or tenofovir alafenamide on fertility are available. 
Nema dostupnih podataka o učinku darunavira, kobicistata, emtricitabina ni tenofoviralafenamida na plodnost u ljudi.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of tenofovir alafenamide has not been studied. 
Utjecaj teškog oštećenja jetrene funkcije (Child-Pugh stadij C) na farmakokinetiku tenofoviralafenamida nije ispitivan.
Co-administration of Symtuza with rifabutin and rifapentine is not recommended. 
Ne preporučuje se istodobna primjena lijeka Symtuza s rifabutinom i rifapentinom.
Use of other antiplatelets not affected by CYP inhibition or induction (e.g. prasugrel) is recommended. 
Preporučuje se se uzimanje drugog antitrombocitnog lijeka na kojeg ne utječe CYP inhibicija ili indukcija (npr. prasugrela).
Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. 
Bolesnici s kroničnim hepatitisom B ili C koji primaju antiretrovirusnu terapiju izloženi su povećanom riziku od razvoja teških jetrenih nuspojava s mogućim smrtnim ishodom.